missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Description
EBI3 is a subunit in two distinct heterodimeric cytokines: interleukin-27 (IL-27) and IL-35 (1-3). Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of naive but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 (also known as TCCR) and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet. IL-35 is composed of EBI3 and the p35 subunit of IL-12 and has been reported to have therapeutic effects against collagen-induced arthritis by expanding the population of regulatory T cells and suppressing Th17 cells. At least two isoform of EBI3 are known to exist.
Specifications
Specifications
| Antigen | EBI3 |
| Applications | Immunoprecipitation, Western Blot |
| Classification | Polyclonal |
| Concentration | 0.13 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 50% glycerol and 0.02% sodium azide; pH 7.3 |
| Gene | EBI3 |
| Gene Accession No. | Q14213 |
| Gene Alias | EBI3, EBV induced gene 3 protein, Epstein Barr virus induced 3, IL 27 subunit beta, IL 27B, IL27B, Interleukin 27 subunit beta |
| Gene Symbols | EBI3 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?